ME02660B - Modulator! jetrenog x receptora - Google Patents

Modulator! jetrenog x receptora

Info

Publication number
ME02660B
ME02660B MEP-2016-289A MEP2016289A ME02660B ME 02660 B ME02660 B ME 02660B ME P2016289 A MEP2016289 A ME P2016289A ME 02660 B ME02660 B ME 02660B
Authority
ME
Montenegro
Prior art keywords
alkyl
nrc
haloalkyl
halogen
optionally substituted
Prior art date
Application number
MEP-2016-289A
Other languages
German (de)
English (en)
French (fr)
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of ME02660B publication Critical patent/ME02660B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)

Claims (18)

1. Jedinjenje predstavljeno slijedećom strukturnom formulom: ili njegova farmaceutski prihvatljiva so, gdje X je N ili CRc, R1 je alkil ili -NRaRb; R2 je H; halogen; -CN; -NRC(O)R; -C(O)OR; -C(O)NRaRb; monociklik heteroaromatik opciono supstituisan sa jednom ili više grupa izabranih iz alkila, - CN, -NRC(O)R, -C(O)OR, -C(O)NRaRb i halogena; monocikličnog nearomatičnog heterocikla opciono supstituisanog sa jednom ili više grupa izabranih iz alkil, halogen, -CN i =O; ili alkil opciono supstituisan jednom ili više grupa izabranih iz halogena, hidroksija, alkoksija, -NRaRb, -NRC(O)R,- NRC(O)O(alkil), -NRC(O)N(R)2, -C(O)OR, tiol, alkiltiol, nitro, -CN, =O, -OC(O)H, -OC(O) (alkil), -OC(O)O(alkil), -OC(O)N(R)2 i -C(O)NRaRb; R3 je alkil, haloalkil, hidroksialkil, alkoksialkil, cikloalkil, monociklični nearomatični heterocikl, monociklični heteroaromatik ili fenil, pri čemu je fenil, monociklični nearomatični heterocikl i monociklična heteroaromatična grupa predstavljena pomoću R3 su opciono supstituisane jednom ili više grupa izabranih iz alkila, halogena, haloalkila, alkoksi, haloalkoksi, nitro i -CN; R4 i R5 nezavisno su halogen, -CN, -OR, -SR, -N(R)2, -C(O)R, -C(O)OR, -OC(O)O(alkil), -C(O)O(haloalkil), -OC(O)R, -C(O)N(R)2, -OC(O)N(R)2, -NRC( O)R, -NRC(O)O(alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS(O)R, -NRSO2R, -NRC(O)N(R)2, -NRSO2N(R)2, haloalkil, haloalkoksi, cikloalkoksi, cikloalkil, monociklični nearomatični heterocikl, monociklični heteroaromatik ili alkil, pri čemu alkil, monociklični nearomatični heterocikl i monociklični heteroaromatik grupa predstavljeni pomoću R4 ili R5 se opciono supstituišu sa jednom ili više grupa izabranih iz -CN, -OR, -SR, -N(R)2, =O, -C(O)R, -C(O)OR, -C(O)O(haloalkil), -OC(O)R, -OC(O)O(alkil), -C(O)N(R )2, -OC(O)N(R)2, -NRC(O)R, -NRC(O)O(alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS (O)R, -NRSO2R, -NRC(O)N(R)2 i -NRSO2N(R)2; R6 je H, halogen, -CN, -OR, -SR, -N(R)2, -C(O)R, -C(O)OR, -OC(O)O(alkil), -C(O)O(haloalkil), -OC(O)R, -C(O)N(R)2, -OC(O)N(R)2, -NRC(O)R, -NRC(O)O( alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS(O)R, -NRSO2R, -NRC(O)N(R)2, -NRSO2 N(R)2, haloalkil, haloalkoksi, cikloalkoksi, cikloalkil ili alkil, pri čemu alkil grupa predstavljena pomoću R6 je opciono supstituisana sa jednom ili više grupa izabranih iz -CN, -OR, -SR, -N(R)2, =O, -C(O)R, -C(O)OR, -C(O)O(haloalkil), -OC(O)R, -OC(O)O(alkil), -C(O)N(R) 2, -OC(O)N(R)2, -NRC(O)R, -NRC(O)O(alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS( O)R, -NRSO2R, -NRC(O)N(R)2 i -NRSO2N(R)2; ili R5 i R6, uzeti zajedno sa atomima ugljenika na koje se oni vjezuju, formiraju monociklični nearomatični heterocikl opciono supstituisan sa jednom ili više grupa izabranih iz alkila, halogena, hidroksialkil, alkoksi alkil, haloalkil i =O; i svaki R nezavisno je H ili alkil; Ra i Rb se nezavisno H, alkil ili Ra i Rb moguće je uzeti zajedno sa azotom na koji se oni spoje da formiraju monociklični nearomatični heterocikl; i Rc je H, alkil, ili halogen.
2. Jedinjenje prema patentnom zahtjevu 1, gdje je: R3 je alkil, haloalkil, hidroksialkil, alkoksialkil, cikloalkil ili fenil, pri čemu fenil grupa predstavljena pomoću R3 je opciono supstituisana sa jednom ili više grupa izabranih iz alkila, halogena, haloalkila, alkoksi, haloalkoksi, azot i -CN; R4 i R5 nezavisno su halogen, -CN, -OR, -SR, -N(R)2, -C(O)R, -C(O)OR, -OC(O)O(alkil), -C(O)O(haloalkil), -OC(O)R, -C(O)N(R)2, -OC(O)N(R)2, -NRC( O)R, -NRC(O)O(alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS(O)R, -NRSO2R, -NRC( O)N(R)2, -NRSO2N(R)2, haloalkil, haloalkoksi, cikloalkoksi, cikloalkil ili alkil, pri čemu je alkil predstavljen pomoću R4 ili R5 opciono supstituisan sa jednom ili više grupa izabranih iz -CN, -OR, -SR, -N(R)2, =O, -C(O)R, -C(O)OR, -C(O)O(haloalkil), -OC(O)R, -OC(O)O(alkil), -C(O)N(R )2, -OC(O)N(R)2, -NRC(O)R, -NRC(O)O(alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS (O)R, -NRSO2R, -NRC(O)N(R)2 i -NRSO2N(R)2; R6 je H, halogen, -CN, -OR, -SR, -N(R)2, -C(O)R, -C(O)OR, -OC(O)O(alkil), -C(O)O(haloalkil), -OC(O)R, -C(O)N(R)2, -OC(O)N(R)2, -NRC(O)R, -NRC(O)O (alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS(O)R, -NRSO2R, -NRC(O)N(R)2, -NRSO 2N(R)2, haloalkil, haloalkoksi, cikloalkoksi, cikloalkil ili alkil, pri čemu alkil grupa predstavljena pomoću R6 se opciono supstituiše sa jednom ili više grupa izabranih iz -CN, -OR, -SR, -N(R)2, =O, -C(O)R, -C(O)OR, -C(O)O(haloalkil), -OC(O)R, -OC(O)O(alkil), -C(O)N(R) 2, -OC(O)N(R)2, -NRC(O)R, -NRC(O)O(alkil), -S(O)R, -SO2R, -SO2N(R)2, -NRS( O)R, -NRSO2R, -NRC(O)N(R)2 i -NRSO2N(R)2.
3. Jedinjenje prema patentnom zahtjevu 1 ili 2, gdje je jedinjenje predstavljeno slijedećom strukturnom formulom: ili njegova farmaceutski prihvatljiva so.
4. Jedinjenje prema patentnom zahtjevu 1 ili 2, gdje je jedinjenje predstavljeno slijedećom strukturnom formulom: ili njegova farmaceutski prihvatljiva so.
5.Jedinjenje iz bilo kog od prijethodnih patentnih zahtjeva, pri čemu: R1 je metil ili -NH2 ; R2 je H ili metil, pri čemu metil grupa predstavljena pomoću R2 se opciono supstituiše sa jednom ili više grupa izabranih iz halogena, hidroksi, alkoksi, -NRaRb,-NRC(O)R, -NRC(O)O(alkil), -NRC(O)N(R)2, -C(O)OR, tiol, alkiltiol, nitro, -CN, =O,-OC(O)H, -OC(O)(alkil), -OC(O)O(alkil), -C(O)NRaRb i -OC(O)N(R)2; R3 je metil, etil, propil, izopropil, tert-butil, sek-butil, izo-butil, -CH2CF3, -CH(CH2F)2, -CH(CHF2)2, -CH(CF3)2, -CF(CH3)2, -CF3, ciklopropil, ciklobutil, ciklopentil, cikloheksil, -C(OH)(CH3)2, -CH(OH)(CH3), ili fenil, pri čemu fenil grupa, predstavljena pomoću R3 , se opciono supstituiše sa jednom ili više grupa izabranih iz alkil, halogen, haloalkil, alkoksi, haloalkoksi, nitro i -CN; i Rc, gdje je prisutan, je H.
6.Jedinjenje iz bilo kod od prijethodnih patentnih zahtjeva, gdje: R1 je metil; R2 je -CH2OH; R3 je izopropil; i R4 i R5 nezavisno su halogen, hidroksi, alkil, cikloalkil, cikloalkoksi, alkoksi, haloalkoksi, haloalkil, -N(R)2, -C(O)OH, -C(O)O(alkil), -C(O)O(haloalkil), -C(O)(alkil), -C(O) N(R)2, -NRC(O)R, -SO2N(R)2, -OC(O)N(R)2, -CN, hidroksialkil ili dihidroksialkil.
7.Jedinjenje prema bilo kom od prijethodnih patentnih zahtjeva, pri čemu R4 i R5 nezavisno su metil, etil, hidroksi, CF3, izopropil, ciklopropil, -CH2OH, -CH(OH)(CH2)(OH), -C(OH)(CH3)2, -CH(OH)(CH3), -CH(OH)(CH2)(CH3), -CH(OH)(CH2)2(CH3), -C(O)NH2, -C(O)N(CH3)2, -C(O)OH, -C(O)NH(CH3), -C(O)CH3, -C (O)CH2CH3, -C(O)O(CH2)(CH3), -C(O)O(tert-butil), -C(O)O(C)(CH3)2(CF3), -NHC(O)CH3,-OCHF2, -OCF3, -OCH2CH3, -OCH(CH3)2 ili -OCH3.
8.Jedinjenje prema bilo kom od prijethodnih patentnih zahtjeva, pri čemu R4 jeste alkil, haloalkil, cikloalkil, alkoksi, ili haloalkoksi
9.Jedinjenje prema bilo kom od prijethodnih patentnih zahtjeva, pri čemu R4 jeste metil, halogenisani metil, ciklopropil, -OCHF2 ili -OCH3.
10.Jedinjenje iz bilo kog od prijethodnih patentnih zahtjeva, gde R4 jesta CF3.
11.Jedinjenje iz bilo kog od prethodnih patentnih zahtjeva, pri čemu R5 jeste -C(OH)(CH3)2.
12.Jedinjenje iz patentnog zahtjeva 1, pri čemu je jedinjenje predstavljeno strukturnom formulom izabranom iz i ili njegove farmaceutski prihvatljive soli.
13.Jedinjenje prema patentnom zahtjevu 1, pri čemu je jedinjenje predstavljeno slijedećom strukturnom formulom: ili njegova farmaceutski prihvatljiva so.
14.Farmaceutska supstanca koja obuhvata farmaceutski nosač ili razblaživač i jedinjenje prema bilo kojem od patentnih zahtjeva 1-13.
15.Jedinjenje prema bilo kojem od patentnih zahtjeva 1 -13 za upotrebu u liječenju ispitanika sa bolešću ili poremećajem koji se liječi pojačavanjem aktivnosti jetrenog X receptora (LXR).
16. Upotreba iz patentnog zahtjeva 15, pri čemu je bolest ili poremećaj hiperlipidemija, hiperholesterolemija, hiperlipoproteinemija, hipertrigliceridemija, lipodistrofija, steatoza jetre (bolest masne jetre), nealkoholni steatohepatitis (NASH), nealkoholna bolest masne jetre (NAFLD), hiperglicemija, otpornost na insulin, dijabetes melitus, dislipidemija, ateroskleroza, bolest kamena u žuči, akne vulgaris, dermatitis, psorijaza, kontaktni dermatitis, atopični dermatitis, ekcem, rane na koži, starijenje kože, starijenje usled izloženosti zracima, stvaranje bora, dijabetes, Nieman-Pikova bolest tipa C, Parkinsonova bolest, Alchajmerova bolest, upala, ksantom, gojaznost, metabolički sindrom, X sindrom, moždani udar, periferna bolest začepljenja, gubitak memorije, dijabetesne neuropatije, proteinurije, glomerulopatije, dijabetesna nefropatija, hipertenzivna nefropatija IGA nefropatija, fokalna segmentalna glomeruloskleroza, hiperfosfatemija, kardiovaskularne komplikacije hiperfosfatemije, kancer ili multipla skelroza.
17.Jedinjenje za upotrebu prema patentnom zahtjevu 16 pri čemu je bolest ili poremećaj ateroskleroza, Alchajmerova bolest, kardiovaskularna bolest, kardiovaskularne komplikacije hiperfosfatemije, ili dermatitisa.
18.Jedinjenje predstavljeno slijedećom strukturnom formulom: ili njegova so, pri čemu: X je N ili CRc. R10 je alkil ili -NRaRb; R20 je H; halogen; -CN; -NRC(O)R; -C(O)OR; -C(O)NRaRb; monociklični heteroaromatik opciono supstituisan sa jednom ili više grupa izabranih iz alkila, -CN, -NRC(O)R, -C(O)OR, -C(O)NRaRb i halogena; monocikličnog nearomatičnog heterocikla opciono supstituisanog jednom ili više grupa izabranih iz alkila, halogena, -CN i =O; ili alkil opciono supstituisan jednom ili više grupa izabranih iz halogena, hidroksija, alkoksija, -NRaRb, -NRC(O)R,-NRC(O)O(alki), -NRC(O)N(R)2, -C(O)OR, tiol, alkitiol, nitro, -CN, =O, -OC(O)H, -OC(O) (alkil), -OC(O)O(alkil), -OC(O)N(R)2, -C(O)NRaRb, i-O(zaštitna grupa); R30 je alkil, haloalkil, hidroksialkil, alkoksialkil, cikloalkil ili fenil, pri čemu fenil grupa predstavljena pomoću R30 je opciono supstituisana sa jednom ili više grupa izabranih iz alkil, haloalkil, alkoksi, haloalkoksi, nitro i -CN; svaki R nezavisno je H ili alkil; Ra i Rb su nezavisno H, alkil ili Ra i Rb može da se uzme zajedno sa azotom na koji se oni spoje da formiraju monociklični nearomatični heterocikl; i Rc je H, alkil, ili halogen.
MEP-2016-289A 2012-03-16 2013-03-14 Modulator! jetrenog x receptora ME02660B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612063P 2012-03-16 2012-03-16
PCT/US2013/031250 WO2013138568A1 (en) 2012-03-16 2013-03-14 Liver x reception modulators
EP13712103.4A EP2825542B1 (en) 2012-03-16 2013-03-14 Liver x receptor modulators

Publications (1)

Publication Number Publication Date
ME02660B true ME02660B (me) 2017-06-20

Family

ID=47997958

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-289A ME02660B (me) 2012-03-16 2013-03-14 Modulator! jetrenog x receptora

Country Status (27)

Country Link
US (5) US9073931B2 (me)
EP (1) EP2825542B1 (me)
JP (3) JP6114815B2 (me)
KR (1) KR102069913B1 (me)
CN (1) CN104203950B (me)
AU (1) AU2013232069B2 (me)
BR (1) BR112014022780A8 (me)
CA (1) CA2865639C (me)
CY (1) CY1118323T1 (me)
DK (1) DK2825542T3 (me)
EA (1) EA026431B1 (me)
ES (1) ES2607113T3 (me)
HR (1) HRP20161690T1 (me)
HU (1) HUE030785T2 (me)
IL (2) IL234301A (me)
LT (1) LT2825542T (me)
ME (1) ME02660B (me)
MX (1) MX354820B (me)
NZ (1) NZ629189A (me)
PL (1) PL2825542T3 (me)
PT (1) PT2825542T (me)
RS (1) RS55532B1 (me)
SG (1) SG11201405323YA (me)
SI (1) SI2825542T1 (me)
SM (2) SMT201700009T1 (me)
WO (1) WO2013138568A1 (me)
ZA (1) ZA201406390B (me)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
SMT201700009T1 (it) * 2012-03-16 2017-03-08 Vitae Pharmaceuticals Inc Modulatori del recettore x del fegato
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
WO2015195922A1 (en) * 2014-06-19 2015-12-23 Vitae Pharmaceuticals, Inc. Compounds for use in treating acute coronary syndrome and related conditions
MX377304B (es) * 2014-08-07 2025-03-07 Vitae Pharmaceuticals Llc Derivados de piperazina como moduladores de los receptores x del hígado.
EP3373935B1 (en) 2015-11-12 2021-09-01 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use
US11648220B2 (en) 2016-01-11 2023-05-16 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
WO2018019911A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sarl Therapeutic combinations to treat red blood cell disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
BR112020023001A2 (pt) 2018-05-15 2021-02-02 Alkahest, Inc. tratamento de doença associada ao envelhecimento com moduladores da leucotrieno a4 hidrolase
US20220127680A1 (en) * 2019-02-28 2022-04-28 The Rockefeller Universtiy Apoe genotyping in cancer prognostics and treatment
CN114126618A (zh) 2019-07-15 2022-03-01 诺华股份有限公司 用肝脏x受体激动剂治疗睑板腺功能障碍的方法
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof
US12575690B2 (en) * 2023-07-26 2026-03-17 Brumate, Inc. Keyed straw

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748247A (en) 1986-10-21 1988-05-31 American Home Products Corporation 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
US5356862A (en) 1990-01-22 1994-10-18 E. I. Du Pont De Nemours And Company Herbicidal sulfonylureas
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
DK0817627T3 (da) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
WO1996012721A1 (en) 1994-10-20 1996-05-02 American Home Products Corporation Indole derivatives useful as serotonergic agents
EP0912513A1 (en) 1996-06-28 1999-05-06 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2258093A1 (en) 1996-06-28 1998-01-08 Mark E. Duggan Fibrinogen receptor antagonists
JP2000514427A (ja) 1996-06-28 2000-10-31 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
FR2761073B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761070B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
DE19802235A1 (de) 1998-01-22 1999-07-29 Bayer Ag Mit tricyclischen Indolen substituierte Oxazolidinone
IL129484A0 (en) 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
WO2000068202A1 (en) 1999-05-06 2000-11-16 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (it) * 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
WO2001030331A2 (en) 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
JP2003525874A (ja) 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
DE60113865T2 (de) 2000-07-31 2006-07-20 Vernalis Research Ltd., Winnersh Piperazin derivate
WO2002059082A2 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
FR2829766A1 (fr) 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
CA2471562A1 (en) 2001-12-21 2003-07-24 King Pharmaceuticals Research And Development, Inc. Tyrosyl derivatives and their use as p2x7 receptor modulators
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
CA2560311A1 (en) 2004-04-08 2005-10-20 Novartis Ag Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2005113526A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
DE602005019465D1 (de) 2004-12-15 2010-04-01 Hoffmann La Roche Bi- und trizyklische substituierte phenyl-methanone als inhibitoren von glycin-i (glyt-1)-transportern zur behandlung der alzheimer-krankheit
US20090238761A1 (en) 2005-01-03 2009-09-24 Universita Degli Studi Di Siena Novel Aryl Piperazine Derivatives With Medical Utility
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
BRPI0612988A2 (pt) 2005-07-14 2010-12-14 Hoffmann La Roche derivados de indol-3-il-carbonil-espiro-piperidina como antagonistas de receptor v1a
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP4882127B2 (ja) * 2005-11-16 2012-02-22 株式会社ジェイテクト 位置調整式ステアリング装置
JP2007137810A (ja) * 2005-11-17 2007-06-07 Sankyo Co Ltd インドール化合物を含有する医薬
WO2007065820A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP5746860B2 (ja) 2007-04-09 2015-07-08 メチルジーン インコーポレイテッド ヒストンデアセチラーゼ阻害剤
AU2008268442A1 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
CN101952293A (zh) * 2007-12-21 2011-01-19 惠氏有限责任公司 吡唑并[1,5-a]嘧啶化合物
NZ587215A (en) 2008-01-22 2012-08-31 Takeda Pharmaceutical Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
US20090192147A1 (en) 2008-01-30 2009-07-30 Wyeth [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
WO2009118411A2 (en) 2008-03-28 2009-10-01 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
ES2462290T3 (es) 2009-06-08 2014-05-22 Grünenthal GmbH Bencimidazoles, benzotiazoles y benzoxazoles sustituidos
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
CA2772522A1 (en) 2009-09-11 2011-03-17 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011071725A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
KR101302474B1 (ko) 2012-02-20 2013-09-02 주식회사 케이씨씨 내충격성 및 불연성이 우수한 진공단열재용 봉지부재
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
SMT201700009T1 (it) 2012-03-16 2017-03-08 Vitae Pharmaceuticals Inc Modulatori del recettore x del fegato

Also Published As

Publication number Publication date
US20170007603A1 (en) 2017-01-12
SMT201700009T1 (it) 2017-03-08
AU2013232069A1 (en) 2014-09-18
JP2017128589A (ja) 2017-07-27
HK1206332A1 (en) 2016-01-08
ES2607113T3 (es) 2017-03-29
EP2825542A1 (en) 2015-01-21
JP2015514061A (ja) 2015-05-18
EA026431B1 (ru) 2017-04-28
IL251897A0 (en) 2017-06-29
HRP20161690T1 (hr) 2017-02-24
JP2019006813A (ja) 2019-01-17
MX2014011104A (es) 2014-12-05
NZ629189A (en) 2016-08-26
JP6114815B2 (ja) 2017-04-12
EA201491610A1 (ru) 2014-12-30
US9073931B2 (en) 2015-07-07
US20150065515A1 (en) 2015-03-05
WO2013138568A8 (en) 2014-08-28
CN104203950A (zh) 2014-12-10
US20180117041A1 (en) 2018-05-03
SI2825542T1 (sl) 2017-01-31
US20200138812A1 (en) 2020-05-07
SG11201405323YA (en) 2014-10-30
CA2865639C (en) 2020-12-22
KR102069913B1 (ko) 2020-01-23
DK2825542T3 (en) 2017-01-09
PT2825542T (pt) 2016-12-20
KR20140135829A (ko) 2014-11-26
AU2013232069B2 (en) 2017-07-13
HUE030785T2 (en) 2017-06-28
US9416135B2 (en) 2016-08-16
BR112014022780A2 (pt) 2017-06-20
US20150336963A1 (en) 2015-11-26
CA2865639A1 (en) 2013-09-19
ZA201406390B (en) 2019-11-27
RS55532B1 (sr) 2017-05-31
SMT201700009B (it) 2017-03-08
CN104203950B (zh) 2016-08-24
US9707232B2 (en) 2017-07-18
WO2013138568A1 (en) 2013-09-19
CY1118323T1 (el) 2017-06-28
EP2825542B1 (en) 2016-09-14
BR112014022780A8 (pt) 2021-06-15
MX354820B (es) 2018-03-21
LT2825542T (lt) 2016-12-27
IL234301A (en) 2017-09-28
PL2825542T3 (pl) 2017-05-31

Similar Documents

Publication Publication Date Title
ME02534B (me) Modulatori x receptora iz jetre
HRP20161690T1 (hr) Modulatori jetrenog receptora x
JP2015514061A5 (me)
JP2015510892A5 (me)
ME02685B (me) Kristalni oblik pemirolasta
AR122395A2 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
PE20160679A1 (es) Inhibidores de pirimidina del fgfr4
AR084824A1 (es) Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
JP2020519654A5 (me)
AR110155A2 (es) ALCOHOLES TRIFLUOROMETÍLICOS COMO MODULADORES DE RORgT
ME02537B (me) Derivati tienopiridona korisni kao ampk aktivatori
HRP20190805T1 (hr) Spojevi triazolopirimidina i njihova uporaba
WO2014174524A8 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
EP2557095A4 (en) METHOD FOR PRODUCING A WATER ABSORBING POLYACRYLIC ACID (SALT) RESIN POWDER, AND WATER ABSORBING POLYACRYLIC ACID (SALT) RESIN POWDER
EP2657264A4 (en) METHOD FOR PRODUCING A HYPER-BRANCHED POLYCARBOXYLIC ACID CEMENT DISPERSIBLE AGENT
EP2922812A4 (en) METHOD FOR PRODUCING A SALT FROM A SULFURIZED HYDROXYAROMATIC ALKYL SUBSTITUTED COMPOSITION
JP2016532669A5 (me)
EP3063258A4 (en) PROCESS FOR PREPARING AN OVERBASED SALT FROM A SULFURIZED, ALKYL SUBSTITUTED AND HYDROXYAROMATIC COMPOSITION
EP2912018A4 (en) PROCESS AND CATALYST FOR THE PREPARATION OF PYRIDINE AND ALKYL DERIVATIVES THEREOF
BR112014030126A2 (pt) processos para produzir certos 2-(piridino-3-il)tiazóis
EP2787012A4 (en) PROCESS FOR PREPARING A STRONG ABSORBENT POLYMER
EP2772564A4 (en) INDIUM SPUTTERTARGET AND MANUFACTURING METHOD THEREFOR
EP2868671A4 (en) PREPARATION METHOD FOR (METH) ACRYLIC RESIN COMPOSITION
WO2013140265A3 (en) Fertility enhancing agent
CL2013000929A1 (es) Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt.